Becton Dickinson and Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 203.75.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Becton Dickinson and Co's Score
Industry at a Glance
Industry Ranking
3 / 208
Overall Ranking
47 / 4592
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Buy
Current Rating
203.751
Target Price
+7.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Becton Dickinson and Co Highlights
StrengthsRisks
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.84B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 71.28%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 71.28%.
Undervalued
The company’s latest PE is 34.44, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 268.89M shares, increasing 0.03% quarter-over-quarter.
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Ticker SymbolBDX
CompanyBecton Dickinson and Co
CEOPolen (Thomas E)
Websitehttps://www.bd.com/
FAQs
What is the current price of Becton Dickinson and Co (BDX)?
The current price of Becton Dickinson and Co (BDX) is 200.300.
What is the symbol of Becton Dickinson and Co?
The ticker symbol of Becton Dickinson and Co is BDX.
What is the 52-week high of Becton Dickinson and Co?
The 52-week high of Becton Dickinson and Co is 251.985.
What is the 52-week low of Becton Dickinson and Co?
The 52-week low of Becton Dickinson and Co is 162.290.
What is the market capitalization of Becton Dickinson and Co?
The market capitalization of Becton Dickinson and Co is 57.17B.
What is the net income of Becton Dickinson and Co?
The net income of Becton Dickinson and Co is 1.68B.
Is Becton Dickinson and Co (BDX) currently rated as Buy, Hold, or Sell?
According to analysts, Becton Dickinson and Co (BDX) has an overall rating of Buy, with a price target of 203.751.
What is the Earnings Per Share (EPS TTM) of Becton Dickinson and Co (BDX)?
The Earnings Per Share (EPS TTM) of Becton Dickinson and Co (BDX) is 5.834.